Download - Brexit webinar -- What would britain leaving the EU would mean for the uk life science sector?
Produced by Biotech and Money Ltd
Brexit Webinar
What would Britain leaving the EU mean
for the UK life science sector?
Produced by Biotech and Money Ltd
Brexit Webinar 21st June at 16.30 BST
Join a panel of industry stakeholders, debate the practical, financial and legal consequences of the Brexit vote, including:
David MacMurchy Head of Life Sciences
EY
Angus Dalgleish Prof of Oncology
SGUL
Mark Thompson Partner
Sidley Austin
Produced by Biotech and Money Ltd
Meet the Speakers21st June at 16.30 BST
David MacMurchy Head of Life SciencesEY
David is a partner at EY in the Advisory Practice where he is responsible for the global advisory work with life science clients and leads the UK and Ireland advisory life science practice. Throughout his career, David has led many global and country-specific projects, particularly in the USA and Europe.
Produced by Biotech and Money Ltd
Meet the Speakers21st June at 16.30 BST
Prof Angus DalgleishProfessor of OncologySGUL
Angus is a Professor of Oncology with the Institute of Infection and Immunity at St Seorge’s University of London. Angus believes that the problems he has encountered both professionally and locally stem from ill thought through EU directives which are strangling the country’s ability to function effectively.
Produced by Biotech and Money Ltd
Meet the Speakers21st June at 16.30 BST
Mark ThompsonPartnerSidley Austin
Mark Thompson, Partner, Sidley AustinMark has over 20 years of experience advising clients on international M&A and private equity transactions, has a particular focus on life sciences, and with extensive experience advising clients making investments in the U.S., Western and Eastern Europe, Russia, Africa and the Middle East.
Produced by Biotech and Money Ltd
You will learn:21st June at 16.30 BST
Research & Talent:
• How big would an exodus of international scientific talent from the UK be?
• How important would the loss of coordination roles in EU collaborations be and how
would this affect revenues?
Produced by Biotech and Money Ltd
You will learn:21st June at 16.30 BST
Regulation:
• With the European Medicines Agency forced to leave London in an out-vote, what extent
would Britain’s role in regulating medicine be diminished?
• What could the regulatory environment the UK medicines look like post-Brexit?
Produced by Biotech and Money Ltd
You will learn:21st June at 16.30 BST
Investment:
• In what ways would Brexit threaten inward investment into UK life sciences?
• Could restoring full sovereignty enable the UK to re-strategise and become more pro-
science?
Produced by Biotech and Money Ltd
You will learn:21st June at 16.30 BST
Future:
• What can life science companies do to cope with the uncertainty of Brexit?
• What should companies be doing to prepare for the eventuality of an exit?
Produced by Biotech and Money Ltd
Register your interest
Date: 21st June
Time: 16.30 BST
Duration: 1h